

APPLICANTS: Chalifou *et al.*  
U.S.A.N.: 09/724,842

grammatical and clerical errors. The cancellation of and/or amendments to the claims are being made solely to expedite prosecution of this application. Applicant reserves the option to further prosecute the same or similar claims in this or in another patent application. No new matter is added. Support for new claims 46-103 is found throughout the specification, *inter alia*, in cancelled claims 1-45, and, 5 pages 3-4 (e.g., claim 46), the end of page 4 to the top of page 5 (e.g., claim 48), page 5 (e.g., claims 49-50), pages 10-12 (e.g., claim 51), page 12-13 (e.g., claim 53), and page 10 (e.g., claim 54.) Accordingly, *claims 46-99 are in the case.*

The Specification has also been amended herein to include the amino acid sequence of A $\beta$  amyloid peptide and various regions thereof. Support for this amendment is found, *inter alia*, in FIG. 10 1 of the Specification. The specification has also been amended to substitute the Attorney Docket number of Applicant's former representative with that of Applicant's current representative. A substitute Specification, showing all of the changes made, is also enclosed herewith for the Examiner's convenience.


#### SUMMARY

15 In view of the above arguments and comments, Applicants respectfully submit that the present case is in condition for allowance, and as such a Notice of Allowance is respectfully requested. If a telephone conversation with Applicants' attorney would help expedite the prosecution of this application, the Examiner is invited to call Applicants' attorney Nicholas P. Triano III at (617) 542-6000.

20 Please apply any charges not covered, or any credits, to Deposit Account 50-0311.



Respectfully submitted,

  
Ivor R. Elrifi, Reg. No. 39,529  
Nicholas P. Triano, III, Reg. No. 36,397  
Attorneys for Applicant(s)

25 MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
30 Tel: (617) 542-6000  
Fax: (617) 542-2241

Dated: September 17, 2001

APPLICANTS: Chalifou *et al.*  
U.S.A.N.: 09/724,842

**Appendix A: marked up versions of amendments to specification showing the changes made**

***In the Specification:***

Replace the text at page 10, line 30 to page 13, line 10 with the following:

- 5 SEQ ID NO: 1 Aβ (1-42, all-D)  
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAI IGLMVGGVVIA
- SEQ ID NO: 2 Aβ (1-40, all-D) DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAI IGLMVGGVV
- SEQ ID NO: 3 Aβ (1-35, all-D) DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAI IGLM
- SEQ ID NO: 4 Aβ (1-28, all-D) DAEFRHDSGYEVHHQKLVFFAEDVGSNK
- SEQ ID NO: 5 Aβ (1-7, all-D) DAEFRHD
- 10 SEQ ID NO: 6 Aβ (10-16, all-D) YEVHHQK
- SEQ ID NO: 7 Aβ (16-21, all-D) KLVFFA
- SEQ ID NO: 8 Aβ (36-42, all-D) VGGVVIA
- SEQ ID NO: 9 Lys-Ile-Val-Phe-Phe-Ala (all-D)
- SEQ ID NO: 10 Lys-Lys-Leu-Val-Phe-Phe-Ala (all-D)
- 15 SEQ ID NO: 11 Lys-Phe-Val-Phe-Phe-Ala (all-D)
- SEQ ID NO: 12 Ala-Phe-Phe-Val-Leu-Lys (all-D)
- SEQ ID NO: 13 Lys-Leu-Val-Phe (all-D)
- SEQ ID NO: 14 Lys-Ala-Val-Phe-Phe-Ala (all-D)
- SEQ ID NO: 15 Lys-Leu-Val-Phe-Phe (all-D)
- 20 SEQ ID NO: 16 Lys-Val-Val-Phe-Phe-Ala (all-D)
- SEQ ID NO: 17 Lys-Ile-Val-Phe-Phe-Ala-NH<sub>2</sub> (all-D)
- SEQ ID NO: 18 Lys-Leu-Val-Phe-Phe-Ala-NH<sub>2</sub> (all-D)
- SEQ ID NO: 19 Lys-Phe-Val-Phe-Phe-Ala-NH<sub>2</sub> (all-D)
- SEQ ID NO: 20 Ala-Phe-Phe-Val-Leu-Lys-NH<sub>2</sub> (all-D)
- 25 SEQ ID NO: 21 Lys-Leu-Val-Phe-NH<sub>2</sub> (all-D)
- SEQ ID NO: 22 Lys-Ala-Val-Phe-Phe-Ala-NH<sub>2</sub> (all-D)
- SEQ ID NO: 23 Lys-Leu-Val-Phe-Phe-NH<sub>2</sub> (all-D)
- SEQ ID NO: 24 Lys-Val-Val-Phe-Phe-Ala-NH<sub>2</sub> (all-D)
- SEQ ID NO: 25 Lys-Leu-Val-Phe-Phe-Ala-Gln (all-D)
- 30 SEQ ID NO: 26 Lys-Leu-Val-Phe-Phe-Ala-Gln-NH<sub>2</sub> (all-D)
- SEQ ID NO: 27 His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Gln (all-D)
- SEQ ID NO: 28 Asp-Asp-Asp (all-D)
- SEQ ID NO: 29 Lys-Val-Asp-Asp-Gln-Asp (all-D)

SEQ ID NO: 30 His-His-Gln-Lys (all-D)

SEQ ID NO: 31 Phe-Phe-NH-CH<sub>2</sub>CH<sub>2</sub>SO<sub>3</sub>H (all-D)

SEQ ID NO: 32 Phe-Phe-NH-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>SO<sub>3</sub>H (all-D)

SEQ ID NO: 33 Phe-Phe-NH-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>SO<sub>3</sub>H (all-D)

5 SEQ ID NO: 34 Phe-Tyr-NH-CH<sub>2</sub>CH<sub>2</sub>SO<sub>3</sub>H (all-D)

SEQ ID NO: 35 Phe-Tyr-NH-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>SO<sub>3</sub>H (all-D)

SEQ ID NO: 36 Phe-Tyr-NH-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>SO<sub>3</sub>H (all-D)

SEQ ID NO: 37 HO<sub>3</sub>SCH<sub>2</sub>CH<sub>2</sub>-Phe-Phe (all-D)

SEQ ID NO: 38 HO<sub>3</sub>SCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-Phe-Phe (all-D)

10 SEQ ID NO: 39 HO<sub>3</sub>SCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-Phe-Phe (all-D)

SEQ ID NO: 40 HO<sub>3</sub>SCH<sub>2</sub>CH<sub>2</sub>-Phe-Tyr (all-D)

SEQ ID NO: 41 HO<sub>3</sub>SCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-Phe-Tyr (all-D)

SEQ ID NO: 42 HO<sub>3</sub>SCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-Phe-Tyr (all-D)

SEQ ID NO: 43 HO<sub>3</sub>SCH<sub>2</sub>CH<sub>2</sub>-Leu-Val-Phe-Phe-Ala (all-D)

15 SEQ ID NO: 44 HO<sub>3</sub>SCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-Leu-Val-Phe-Phe-Ala (all-D)

SEQ ID NO: 45 HO<sub>3</sub>SCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-Leu-Val-Phe-Phe-Ala (all-D)

SEQ ID NO: 46 Leu-Val-Phe-Phe-Ala-NH-CH<sub>2</sub>CH<sub>2</sub>SO<sub>3</sub>H (all-D)

SEQ ID NO: 47 Leu-Val-Phe-Phe-Ala-NH-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>SO<sub>3</sub>H (all-D)

SEQ ID NO: 48 Leu-Val-Phe-Phe-Ala-NH-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>SO<sub>3</sub>H (all-D).

20 The compounds listed above may be modified by removing or inserting one or more amino acid residues, or by substituting one or more amino acid residues with other amino acid or non-amino acid fragments.

The following are exemplary compounds derived from compound 18 (all-D KLVFFA-NH<sub>2</sub> (SEQ ID NO: 18)) by substituting one or two amino acid residue(s) with other amino acids.

25 SEQ ID NO: 49 Lys-Leu-Val-Trp-Phe-Ala-NH<sub>2</sub>(all-D)

SEQ ID NO: 50 Lys-Leu-Val-Phe-Trp-Ala- NH<sub>2</sub> (all-D)

SEQ ID NO: 51 Lys-Leu-Val-Trp-Trp-Ala- NH<sub>2</sub> (all-D)

SEQ ID NO: 52 Lys-Leu-Val-Tyr-Phe-Ala- NH<sub>2</sub> (all-D)

SEQ ID NO: 53 Lys-Leu-Val-Phe-Tyr-Ala- NH<sub>2</sub> (all-D)

30 SEQ ID NO: 54 Lys-Leu-Val-Tyr-Tyr-Ala- NH<sub>2</sub> (all-D)

SEQ ID NO: 55 Lys-Leu-Val-Thi-Phe-Ala- NH<sub>2</sub> (all-D)

SEQ ID NO: 56 Lys-Leu-Val-Phe-Thi-Ala- NH<sub>2</sub> (all-D)

SEQ ID NO: 57 Lys-Leu-Val-Thi-Thi-Ala- NH<sub>2</sub> (all-D)

SEQ ID NO: 58 Lys-Leu-Val-Cha-Phe-Ala- NH<sub>2</sub> (all-D)

APPLICANTS: Chalifour *et al.*  
U.S.A.N.: 09/724,842

SEQ ID NO: 59 Lys-Leu-Val-Phe-Cha-Ala- NH<sub>2</sub> (all-D)

SEQ ID NO: 60 Lys-Leu-Val-Cha-Cha-Ala- NH<sub>2</sub> (all-D)

SEQ ID NO: 61 Lys-Leu-Val-Pgly-Phe-Ala- NH<sub>2</sub> (all-D)

SEQ ID NO: 62 Lys-Leu-Val-Phe-Pgly-Ala- NH<sub>2</sub> (all-D)

**5** SEQ ID NO: 63 Lys-Leu-Val-Pgly-Pgly-Ala- NH<sub>2</sub> (all-D).

TRA 1566507v1